Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4876725
Max Phase: Preclinical
Molecular Formula: C56H72F15N13O17
Molecular Weight: 914.13
Molecule Type: Unknown
Associated Items:
ID: ALA4876725
Max Phase: Preclinical
Molecular Formula: C56H72F15N13O17
Molecular Weight: 914.13
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)NC(=O)[C@H](CCNC(=N)N)NC(=O)[C@@H]1CC(=O)NCCC[C@@H](C(=O)NCCN2CCN(CCCCC3CCN(CC(=O)N4c5ccccc5NC(=O)c5ccccc54)CC3)CC2)N1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C46H67N13O7.5C2HF3O2/c1-31(60)52-44(65)36(15-19-51-46(47)48)55-45(66)37-29-40(61)49-18-8-12-35(53-37)43(64)50-20-24-57-27-25-56(26-28-57)21-7-6-9-32-16-22-58(23-17-32)30-41(62)59-38-13-4-2-10-33(38)42(63)54-34-11-3-5-14-39(34)59;5*3-2(4,5)1(6)7/h2-5,10-11,13-14,32,35-37,53H,6-9,12,15-30H2,1H3,(H,49,61)(H,50,64)(H,54,63)(H,55,66)(H4,47,48,51)(H,52,60,65);5*(H,6,7)/t35-,36-,37-;;;;;/m0...../s1
Standard InChI Key: HUZKXWRKJZMUOH-IRXHXNBUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 914.13 | Molecular Weight (Monoisotopic): 913.5286 | AlogP: 0.18 | #Rotatable Bonds: 17 |
Polar Surface Area: 266.53 | Molecular Species: BASE | HBA: 12 | HBD: 9 |
#RO5 Violations: 3 | HBA (Lipinski): 20 | HBD (Lipinski): 10 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.56 | CX Basic pKa: 12.64 | CX LogP: -2.26 | CX LogD: -5.03 |
Aromatic Rings: 2 | Heavy Atoms: 66 | QED Weighted: 0.06 | Np Likeness Score: -0.44 |
1. Weinhart CG, Wifling D, Schmidt MF, Neu E, Höring C, Clark T, Gmeiner P, Keller M.. (2021) Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity., 213 [PMID:33571911] [10.1016/j.ejmech.2021.113159] |
Source(1):